RECURRENT GLIOBLASTOMA
Clinical trials for RECURRENT GLIOBLASTOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOBLASTOMA trials appear
Sign up with your email to follow new studies for RECURRENT GLIOBLASTOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common diabetes drug help fight aggressive brain tumors?
Disease control Not yet recruitingThis early-phase trial tests sitagliptin, a diabetes medicine, combined with standard bevacizumab in 45 adults with recurrent grade 4 glioma (a fast-growing brain cancer). The goal is to find the safest dose and see if the combination can reduce certain immune cells that may help…
Matched conditions: RECURRENT GLIOBLASTOMA
Phase: PHASE1 • Sponsor: Kailin Yang, MD, PhD • Aim: Disease control
Last updated May 17, 2026 00:32 UTC
-
Supercharged immune cells take on deadly brain tumors
Disease control Not yet recruitingThis early-phase trial tests a new way to treat glioblastoma that has come back after standard therapy. Doctors will deliver specially engineered natural killer (NK) cells directly into the brain to attack the tumor. The study includes 36 adults and aims to find the safest dose a…
Matched conditions: RECURRENT GLIOBLASTOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for brain cancer? experimental drug LMP744 targets recurrent glioblastoma
Disease control Not yet recruitingThis early-stage trial tests a new drug called LMP744 in 40 adults whose glioblastoma (a type of brain cancer) has come back after standard treatment. The drug is given through a vein for 5 days each month for up to a year. The goal is to see if it can shrink tumors or delay canc…
Matched conditions: RECURRENT GLIOBLASTOMA
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New 'T cell Engager' drug targets deadly brain tumors in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called BRiTE in 18 adults with a specific type of glioblastoma brain cancer (EGFRvIII-positive). The drug is designed to help the body's immune T cells attack the tumor. It is given as a continuous 4-day IV infusion every 28 days. The main …
Matched conditions: RECURRENT GLIOBLASTOMA
Phase: PHASE1 • Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP • Aim: Disease control
Last updated May 11, 2026 20:46 UTC